Welcome to our dedicated page for Virnetx Holding SEC filings (Ticker: VHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VirnetX Holding Corp (VHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. VirnetX is an Internet security software and technology company focused on patented Zero Trust Network Access (ZTNA) for secure network communications, and its filings help explain how it reports material events, exchange listing changes, and other corporate actions.
Among the key documents investors may review are current reports on Form 8-K, where VirnetX has described events such as its intention to transfer the listing of its common stock from the New York Stock Exchange to The Nasdaq Stock Market LLC, and the issuance of press releases about significant contracts like its General Services Administration Multiple Award Schedule award. These filings provide formal details about decisions that affect VHC stock trading venues and important business milestones.
VirnetX has also filed Form 25 notifications related to the voluntary removal of its common stock from listing and registration on the NYSE under Section 12(b) of the Securities Exchange Act of 1934. These documents outline the regulatory steps taken to withdraw from that exchange after complying with NYSE rules and SEC requirements.
Through this page, users can monitor VirnetX’s ongoing SEC reporting, including 8-Ks that reference press releases about secure communications initiatives, government and defense partnerships, and other material events. Stock Titan enhances this experience with AI-powered summaries that explain the significance of each filing, highlight key points from lengthy documents, and make it easier to understand how regulatory disclosures relate to VirnetX’s business in secure communications and Zero Trust cybersecurity.
VirnetX Holding Corp (VHC) reported a new equity award for its Chief Financial Officer, Katherine Allanson. On 11/24/2025, she received a stock option (right to buy) covering 30,000 shares of common stock at an exercise price of $20.22 per share, expiring on 11/24/2035.
According to the vesting terms, one-quarter of the option vests and becomes exercisable on the one-year anniversary of the grant date, with an additional one-quarter vesting on each annual anniversary thereafter, assuming she continues as a Service Provider under the company’s 2013 Equity Incentive Plan. If a Change in Control occurs, all unvested shares under this option will fully vest and become exercisable immediately before the transaction is completed.
VirnetX Holding Corp (VHC) reported an insider equity award to its President & CEO and director, Kendall Larsen, who is also a 10% owner. On 11/24/2025, he was granted stock options to buy 50,000 shares of common stock at an exercise price of $20.22 per share, expiring on 11/24/2035, held directly. An additional stock option for 30,000 shares at the same exercise price and expiration date is held indirectly by his spouse.
The options vest over four years: one quarter of the shares vest and become exercisable on the first anniversary of the grant date, and another quarter on each annual anniversary thereafter, subject to continued service under the company’s Amended and Restated 2013 Equity Incentive Plan. If a Change in Control occurs, all then-unvested shares underlying these options will vest and become exercisable immediately before the transaction is completed.
VirnetX Holding Corp (VHC) reported an insider transaction by a director on a Form 4. The reporting person, serving as a director of VirnetX, sold 625 shares of common stock on 11/24/2025 at a price of $20.8885 per share, coded as an "S" transaction (open market or private sale).
After this sale, the director directly beneficially owns 21,709 shares of VirnetX common stock. The filing indicates the form was filed by one reporting person and does not list any derivative securities transactions in Table II.
VirnetX Holding Corporation furnished an Item 7.01 update announcing it was awarded a GSA Schedule contract, as stated in a press release titled “VirnetX Awarded Coveted GSA Schedule Contract - Contract Expands Federal Access to Secure Communications and Zero-Trust Cybersecurity Solutions.” The information, including Exhibit 99.1, was furnished and is not deemed “filed” under Section 18. The exhibits include the press release and the Inline XBRL cover page file.
VirnetX Holding Corporation has filed a Form 25 to remove the listing and/or registration of its common stock, par value $0.0001 per share, from the New York Stock Exchange under Section 12(b) of the Securities Exchange Act of 1934. This action means the company’s common shares will no longer be listed on the NYSE once the process is completed under applicable SEC and exchange rules.
The notification is signed by Chief Executive Officer Kendall Larsen and dated September 22, 2025, formally initiating the delisting and deregistration process for the common stock.
VirnetX Holding Corporation is moving the listing of its common stock from the New York Stock Exchange to The Nasdaq Stock Market LLC. The company notified the NYSE on September 11, 2025 that it intends to voluntarily withdraw its listing and transfer to Nasdaq.
VirnetX expects trading of its common stock on the NYSE to end at market close on or about September 22, 2025, with trading on Nasdaq beginning at market open on or about September 23, 2025. The stock has been approved for listing on Nasdaq and will continue to trade under the ticker symbol “VHC”. The company also issued a press release describing the planned transfer.
VirnetX Holding Corporation reported results for the quarter ended June 30, 2025, showing continued operating losses while maintaining a multi-month cash runway. Revenue was immaterial at $48 thousand for the six months ended June 30, 2025. Operating expenses totaled $8.0 million for the six months, driven by $2.47 million in R&D and $5.57 million in selling, general and administrative expenses.
The company recorded a six-month net loss of $7.3 million (basic loss per share $1.99), and used $6.8 million of cash in operating activities during the period. At June 30, 2025, VirnetX held $17.3 million in cash and $13.9 million of investments available for sale, totaling $31.2 million in liquid resources. Total assets were $41.8 million, total liabilities $8.6 million, and stockholders' equity $33.2 million. The company reported an accumulated deficit of $212.0 million and maintains a full valuation allowance on its deferred tax assets. Management describes ongoing commercialization efforts for VirnetX One™, War Room™, and VirnetX Matrix™, a CRADA with AFRL through 2030, and investments in AI/ML partnerships to support DoD-focused product adoption.
VirnetX Holding Corp Chief Scientist Robert D. Short III reported a Form 4 filing on June 28, 2025, disclosing transactions from June 23, 2025. The insider disposed of 8 shares of Common Stock at $8.06 per share through a withholding transaction (Code F).
Key details of the transaction:
- The shares were withheld by the company for tax purposes related to previously awarded restricted stock units
- Following the transaction, Short holds 31,898 shares directly
- Additionally owns 11,278 shares indirectly through The Short Revocable Living Trust
The transaction was executed under standard tax withholding procedures and does not represent an open market sale by the insider. The filing was signed by Kendall Larsen as attorney-in-fact for Robert D. Short III on June 25, 2025.